Kendall Law Group Investigates SenoRx, Inc. Merger For Shareholders

Kendall Law Group, a national securities firm, is investigating SenoRx, Inc. (NASDAQ: SENO) for shareholders in connection with the proposed sale of the Company to C. R. Bard, Inc. The firm is investigating whether Seno and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. Seno shareholders with information to contribute or seeking additional information about your rights should contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

On May 5, 2010, Seno announced that it had entered into an agreement to be acquired by C.R. Bard for $213 million. According to the agreement, Seno shareholders will receive $11.00 per share, representing a 14% premium over the closing price before the deal was announced. However, SENO stock closed at $10.00 in late April, 2010. The firm is concerned that shareholders will not receive proper value for their investment from the transaction. Since the deal is expected to close by the end of the third quarter of 2010, shareholders are encouraged to contact the firm as soon as possible.

Kendall Law Group, founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in dozens of merger and acquisition cases nationwide, including some of the largest transactions in the United States.

>To order reprints of this article, click here: Reprints